 | |  | |  | |  | |  | |  | |  | |  |
| IJCEP Copyright © 2007-All rights reserved. |
| International Journal of Clinical and Experimental Pathology |
Int J Clin Exp Pathol 2(1), 1-10;2009
Review Article
Diagnostic and Prognostic Biomarkers in Pancreatic Carcinoma
John J. Liang, Eric T. Kimchi, Kevin F. Staveley-O'Carroll and Dongfeng Tan
Departments of Pathology1 and Surgery2, Pennsylvania State University Hershey Medical Center, Hershey, PA, USA and 3Department of
Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Received 12 March 2008; Accepted and available online 12 April 2008
Abstract: Pancreatic ductal carcinoma, one of the leading causes of cancer mortality, is typically diagnosed at an advanced stage, which
significantly contributes to its high mortality rates. Studies have demonstrated that resection of small pancreatic tumors and tumors at
lower stages correlates with improved survival. Detection of pancreatic carcinoma at an early, surgically resectable stage is the key to
decreasing mortality and improving survival. Identification of sensitive diagnostic biomarkers as screening tools is crucial in detecting
preinvasive pancreatic neoplasms. Numerous new DNA-, RNA- and protein-based biomarkers have been extensively investigated. This
review aims to provide an update on these molecular markers, including biomarkers from blood, tissue as well as pancreatic juice and
cystic fluid. These biomarkers hold potential utility in early diagnosis and prognostification of pancreatic ductal carcinoma, though many of
which need to be validated in large-scale prospective studies before they can be used in clinical settings. (IJCEP803009).
Key Words: Pancreatic ductal carcinoma, molecular biomarkers
Full text PDF
Address all correspondences to: Dongfeng Tan, MD, Department of Pathology and Laboratory Medicine, Unit 85, The University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel: (713) 745-4977, Fax: (713) 745-1105,
E-mail: dtan@mdanderson.org.
Review Article
Diagnostic and Prognostic Biomarkers in Pancreatic Carcinoma
John J. Liang, Eric T. Kimchi, Kevin F. Staveley-O'Carroll and Dongfeng Tan
Departments of Pathology1 and Surgery2, Pennsylvania State University Hershey Medical Center, Hershey, PA, USA and 3Department of
Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Received 12 March 2008; Accepted and available online 12 April 2008
Abstract: Pancreatic ductal carcinoma, one of the leading causes of cancer mortality, is typically diagnosed at an advanced stage, which
significantly contributes to its high mortality rates. Studies have demonstrated that resection of small pancreatic tumors and tumors at
lower stages correlates with improved survival. Detection of pancreatic carcinoma at an early, surgically resectable stage is the key to
decreasing mortality and improving survival. Identification of sensitive diagnostic biomarkers as screening tools is crucial in detecting
preinvasive pancreatic neoplasms. Numerous new DNA-, RNA- and protein-based biomarkers have been extensively investigated. This
review aims to provide an update on these molecular markers, including biomarkers from blood, tissue as well as pancreatic juice and
cystic fluid. These biomarkers hold potential utility in early diagnosis and prognostification of pancreatic ductal carcinoma, though many of
which need to be validated in large-scale prospective studies before they can be used in clinical settings. (IJCEP803009).
Key Words: Pancreatic ductal carcinoma, molecular biomarkers
Full text PDF
Address all correspondences to: Dongfeng Tan, MD, Department of Pathology and Laboratory Medicine, Unit 85, The University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel: (713) 745-4977, Fax: (713) 745-1105,
E-mail: dtan@mdanderson.org.